Status:

COMPLETED

Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors

Lead Sponsor:

VA Office of Research and Development

Collaborating Sponsors:

Oregon Health and Science University

Conditions:

Parkinson Disease

Dyskinesia, Drug-Induced

Eligibility:

All Genders

50+ years

Brief Summary

In this study, the investigators will examine the association of statin use and dyskinesia in a convenience sample Parkinson's disease patients in the Veterans Administration Health Care System.

Detailed Description

Long term treatment with levodopa, the gold standard treatment of Parkinson's disease (PD), can lead to the development of abnormal involuntary movements called levodopa induced dyskinesia (LID). The ...

Eligibility Criteria

Inclusion

  • Parkinson's Disease
  • Age diagnosed with Parkinson's Disease greater than or equal to 50 years
  • Treatment with levodopa greater than or equal to 5 years

Exclusion

  • Deep Brain stimulation
  • Unable to stand for 1 minute intervals, or sensory deficits in the feet
  • Significant cognitive impairment as measured by the Montreal Cognitive Assessment score of \< 18
  • Subjects with unstable medical or psychiatric conditions (including hallucinations).
  • History of unstable medical conditions (i.e. active cardiac disease, recent unwellness, surgery etc.)
  • Current use of drugs that may affect parkinsonism or dyskinesia:
  • dopamine receptor blocking medications
  • depakote
  • lithium
  • amiodarone
  • tetrabenazine
  • metoclopramide
  • dronabinol
  • and illicit drugs such as marijuana (THC)
  • cocaine
  • methamphetamine
  • Statins other than simvastatin or lovastatin, atorvastatin ie. fluvastatin (rationale is that while all other statins are thought to not cross the blood brain barrier well, the central nervous system penetrating nature of others is not perfectly clear and could confound results)

Key Trial Info

Start Date :

August 22 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

March 31 2024

Estimated Enrollment :

93 Patients enrolled

Trial Details

Trial ID

NCT04064294

Start Date

August 22 2019

End Date

March 31 2024

Last Update

April 11 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

VA Portland Health Care System, Portland, OR

Portland, Oregon, United States, 97207-2964

2

Oregon Health & Science University

Portland, Oregon, United States, 97239not

3

VA Puget Sound Health Care System Seattle Division, Seattle, WA

Seattle, Washington, United States, 98108